期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.620361
关键词
kynurenine 3-monooxygenase; colorectal cancer; overall survival; metastasis; stemness
类别
资金
- Taiwan Clinical Oncology Research Foundation
- Ministry of Science and Technology, Taiwan [MOST 106-2314-B-075-062, 109-2314-B-075-081-MY3]
- Yen Tjing Ling Medical Foundation [CI-108-19]
- Taipei Veterans General Hospital [V109C-151, V110C-189]
High expression of KMO in CRC is associated with higher metastasis and poorer survival rates. Knockdown of KMO reduces the expression of cancer stem cell markers and the invasion abilities of CRC cells, while inhibition of KMO enzymatic activity suppresses CRC cell motility.
Colorectal cancer (CRC) is a leading cause of cancer-related deaths. Because of the lack of reliable prognostic and predictive biomarkers for CRC, most patients are often diagnosed at a late stage. The tryptophan-kynurenine pathway plays a crucial role in promoting cancer progression. Kynurenine is considered an oncometabolite in colon cancer, and its downstream metabolites are also associated with CRC. Kynurenine 3-monooxygenase (KMO), a pivotal enzyme that catalyzes kynurenine metabolism, is essential for several cellular processes. In the current study, we explored the role of KMO in CRC. Immunohistochemical results showed that KMO was upregulated in CRC tissues relative to paired healthy tissue and polyps. Moreover, CRC patients with higher KMO expression were associated with higher metastasis and poorer survival rates. Knockdown of KMO decreased the expression of cancer stem cell markers, as well as the sphere-forming, migration, and invasion abilities of CRC cells. Additionally, blockade of the enzymatic activity of KMO using an inhibitor suppressed sphere formation and cell motility in CRC cells. These findings suggest the clinical relevance of KMO in CRC tumorigenesis and aggressiveness.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据